Massmutual Trust Co. FSB ADV Has $2.37 Million Stock Holdings in Inspire Medical Systems, Inc. (NYSE:INSP)

Massmutual Trust Co. FSB ADV decreased its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 0.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,229 shares of the company’s stock after selling 62 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Inspire Medical Systems were worth $2,370,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Van ECK Associates Corp raised its stake in Inspire Medical Systems by 7.5% in the 2nd quarter. Van ECK Associates Corp now owns 1,029 shares of the company’s stock valued at $138,000 after acquiring an additional 72 shares during the period. Amalgamated Bank raised its holdings in Inspire Medical Systems by 4.1% in the 2nd quarter. Amalgamated Bank now owns 2,005 shares of the company’s stock valued at $268,000 after acquiring an additional 79 shares during the period. The Manufacturers Life Insurance Company lifted its position in Inspire Medical Systems by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 21,193 shares of the company’s stock worth $2,836,000 after acquiring an additional 92 shares during the last quarter. Bessemer Group Inc. boosted its holdings in shares of Inspire Medical Systems by 1.2% during the first quarter. Bessemer Group Inc. now owns 8,475 shares of the company’s stock worth $1,820,000 after acquiring an additional 100 shares during the period. Finally, Treasurer of the State of North Carolina increased its stake in shares of Inspire Medical Systems by 1.0% during the fourth quarter. Treasurer of the State of North Carolina now owns 12,750 shares of the company’s stock worth $2,594,000 after purchasing an additional 120 shares during the period. Institutional investors own 94.91% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on INSP. Truist Financial reaffirmed a “buy” rating and issued a $240.00 price objective (up from $217.00) on shares of Inspire Medical Systems in a report on Monday. Morgan Stanley decreased their target price on shares of Inspire Medical Systems from $250.00 to $210.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. Stifel Nicolaus dropped their price target on shares of Inspire Medical Systems from $210.00 to $170.00 and set a “hold” rating for the company in a research report on Monday, June 24th. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, August 7th. Finally, KeyCorp lowered their target price on Inspire Medical Systems from $278.00 to $236.00 and set an “overweight” rating for the company in a research note on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems currently has an average rating of “Moderate Buy” and an average target price of $216.62.

Insider Buying and Selling

In related news, Director Shawn Mccormick sold 800 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the sale, the director now directly owns 23,140 shares in the company, valued at approximately $5,090,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Shawn Mccormick sold 800 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the transaction, the director now owns 23,140 shares of the company’s stock, valued at $5,090,800. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Randy Ban sold 4,861 shares of the business’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $188.55, for a total transaction of $916,541.55. Following the transaction, the insider now owns 3,056 shares of the company’s stock, valued at $576,208.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 5,692 shares of company stock valued at $1,099,207. 4.10% of the stock is owned by insiders.

Inspire Medical Systems Price Performance

INSP stock opened at $205.03 on Friday. The company’s 50-day moving average is $188.70 and its 200-day moving average is $183.02. The stock has a market capitalization of $6.09 billion, a PE ratio of -372.78 and a beta of 1.33. Inspire Medical Systems, Inc. has a 1 year low of $123.00 and a 1 year high of $257.40.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.14) by $0.46. The firm had revenue of $195.89 million during the quarter, compared to analyst estimates of $189.08 million. Inspire Medical Systems had a net margin of 0.85% and a return on equity of 1.03%. The company’s revenue for the quarter was up 29.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.41) EPS. On average, analysts anticipate that Inspire Medical Systems, Inc. will post 0.75 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.